Lumida
/SNDX
⌘K
Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SNDX
$18.18USD-3.40%-0.64 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$18 – $19

52W RANGE

$13
$26

AI Summary

Stalk
Sell NowMedium

The stock failed its key support cluster near earlier lows and now trades below all major EMAs, signaling a breakdown rather than a pullback. The medium-term structure is bearish with further downside likely as supply overwhelms demand, and short-term price momentum confirms unfavorable timing. We are selling now into the continued decline, targeting participation in the accelerating down move.

  • Revuforj and Niktimvo generate ~$200M annually, validating commercial viability
  • Upcoming clinical data readouts could act as major growth catalysts
  • Profit margins are deeply negative and earnings yield remains below zero
Full analysis →
Insider Trades19 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 8, 2026SellSNDXMichael A MetzgerChief Executive Officer64,750$15.31$1.6B-28.96%+39.95%$991.3K+0.00%10b5-1Buy Now
Jun 11, 2026SellSNDXNicholas A.J. BotwoodHead of R&D, CMO119,265$16.15$1.6B-28.96%+39.95%$1.9M-3.67%10b5-1Buy Now
Jun 1, 2026SellSNDXKeith A. GoldanChief Financial Officer1,177$18.99$1.6B-28.96%+39.95%$22.4K-0.84%Buy Now
Jun 1, 2026SellSNDXMichael A MetzgerChief Executive Officer6,847$18.99$1.6B-28.96%+39.95%$130.0K-1.39%Buy Now
Feb 9, 2026SellSNDXKeith A. GoldanChief Financial Officer3,410$21.03$1.6B-28.96%+39.95%$71.7K-2.37%Buy Now
Feb 9, 2026SellSNDXMichael A MetzgerChief Executive Officer17,159$21.03$1.6B-28.96%+39.95%$360.8K-3.37%Buy Now
Feb 6, 2026SellSNDXKeith A. GoldanChief Financial Officer2,082$20.62$1.6B-28.96%+39.95%$42.9K-0.79%Buy Now
Feb 6, 2026SellSNDXMichael A MetzgerChief Executive Officer7,412$20.62$1.6B-28.96%+39.95%$152.8K-0.78%Buy Now
Dec 1, 2025SellSNDXKeith A. GoldanChief Financial Officer1,224$19.12$1.6B-28.96%+39.95%$23.4K-1.31%Buy Now
Sep 8, 2025SellSNDXMichael A MetzgerChief Executive Officer314,614$13.66$1.6B-28.96%+39.95%$4.3M+0.00%10b5-1Buy Now
Jul 16, 2025SellSNDXKeith A. GoldanChief Financial Officer1,296$9.29$1.6B-28.96%+39.95%$12.0K-1.38%Buy Now
Jul 16, 2025SellSNDXMichael A MetzgerChief Executive Officer7,534$9.29$1.6B-28.96%+39.95%$70.0K-2.46%Buy Now
May 16, 2025BuySNDXNicholas A.J. BotwoodHead of R&D, CMO11,765$8.99$1.6B-28.96%+39.95%$105.8K+50.28%Buy Now
Mar 14, 2025BuySNDXMichael A MetzgerChief Executive Officer6,074$7.20$1.6B-28.96%+39.95%$43.7K+2.02%Buy Now
Mar 4, 2025SellSNDXMichael A MetzgerChief Executive Officer15,628$11.12$1.6B-28.96%+39.95%$173.8K+0.00%10b5-1Buy Now
Feb 10, 2025SellSNDXKeith A. GoldanChief Financial Officer3,777$15.50$1.6B-28.96%+39.95%$58.6K-4.00%Buy Now
Feb 10, 2025SellSNDXNeil GallagherPresident, Head of R&D4,618$15.50$1.6B-28.96%+39.95%$71.6K-5.15%Buy Now
Feb 10, 2025SellSNDXMichael A MetzgerChief Executive Officer13,288$15.50$1.6B-28.96%+39.95%$206.0K-4.24%Buy Now
Jun 14, 2024BuySNDXKeith A. GoldanChief Financial Officer1,250$20.03$1.6B-28.96%+39.95%$25.0K+2.43%Buy Now